Therapeutic Areas

The 25th World Congress of Dermatology Singapore 2023 and the strategic importance of the Asian markets

After its recent entry into the Australian and New Zealand markets, IBSA continues its expansion with its aesthetic medicine products in APAC (Asia Pacific) countries, through agreements with local distributors, aimed at driving an increasingly widespread presence.

IBSA choses to be represented by the Neoasia (S) Pte. Ltd. group in Malaysia, Singapore, Vietnam, Philippines and Indonesia, while in Japan its distributor is J. Hewitt; for the markets of Hong Kong, Macao and India, IBSA partnered with Alma Lasers.

Asia represents a strategic market with great potential, with an expected CAGR up to 2031 of 8.8% in the injection aesthetic medicine area. The strategic importance of the APAC countries is also confirmed by IBSA’s participation in the 25th World Congress of Dermatology Singapore 2023, which was held from 3 to 8 July and which involved the leading international experts in this field.

IBSA’S KNOW-HOW AT THE SINGAPORE CONGRESS

IBSA at the World Congress of Dermatology in Singapore
From the left, the speakers of the Symposium: SUZANNE WEI NA CHENG, MD from Singapore; OFIR ARTZI, MD From Israel and CARA MCDONALD, MD from Australia.
From the left, the speakers of the Symposium: SUZANNE WEI NA CHENG, MD from Singapore; OFIR ARTZI, MD From Israel and CARA MCDONALD, MD from Australia.

The World Congress of Dermatology is one of the most important international events in this therapeutic area. The congress takes place every four years, and brings together the major actors from all over the world, to take stock of the state of the art and the latest news in the field of dermatology.

IBSA’s Derma division took part in the event by organising a symposium with the leading experts in dermatology and aesthetic medicine. The meeting – entitled Hybrid Cooperative Complexes (HCCS): the latest frontier of hyaluronic acid-based treatment for face and body skin restoration – was an opportunity to present the last frontier of hyaluronic acid-based treatments, namely cooperative hybrid complexes.

Indeed, IBSA can respond to multiple aesthetic problems of both the face and the body with products based on Ultrapure hyaluronic acid, developed with Nahyco® patented technology. This formulation has also proved to be significant in a demanding market such as the Asian one, which is increasingly looking for innovative products, aimed at responding to still not fully satisfied needs.

Latest news